Jin Rong Jie·2025-12-23 02:50Core Viewpoint - The launch of Manlejing® Melatonin Granules by Dain Pharmaceutical in collaboration with Alibaba Health addresses sleep difficulties in children aged 6 to 15 with neurodevelopmental disorders, marking a significant outcome of their strategic partnership established in October 2023 [1][7]. Group 1: Product Launch and Market Need - Sleep disorders are common and challenging comorbidities in children with neurodevelopmental disorders, particularly in those with Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD) [5]. - Long-term sleep difficulties severely impact children's growth, behavior, and emotional well-being, creating significant challenges for families [5]. - There is a limited availability of safe and effective medications specifically approved for this demographic in China, highlighting a critical clinical need [5]. Group 2: Clinical Data and Safety - Clinical data indicates that the use of Manlejing® can significantly shorten sleep onset latency and improve abnormal behaviors such as irritability and hyperactivity over long-term use [6]. - A six-month follow-up showed no serious adverse reactions, dependency, or withdrawal risks, making it suitable for long-term use in children [6]. Group 3: Strategic Collaboration and Future Plans - Dain Pharmaceutical aims to focus on the development and introduction of pediatric medications and health products, emphasizing a tailored approach to children's medications [6]. - Alibaba Health's role as a strategic partner is to connect with a vast potential user base and provide professional pharmaceutical services, ensuring safe medication use through authoritative content and strict prescription processes [6]. - The collaboration is part of Alibaba Health's strategy to deepen its engagement in vertical health management for specific populations, aiming to provide comprehensive solutions for pharmaceutical companies [7].